vs
Side-by-side financial comparison of CIVISTA BANCSHARES, INC. (CIVB) and Telesat Corp (TSAT). Click either name above to swap in a different company.
Telesat Corp is the larger business by last-quarter revenue ($73.8M vs $47.3M, roughly 1.6× CIVISTA BANCSHARES, INC.). CIVISTA BANCSHARES, INC. runs the higher net margin — 31.7% vs -119.8%, a 151.5% gap on every dollar of revenue. Over the past eight quarters, CIVISTA BANCSHARES, INC.'s revenue compounded faster (11.3% CAGR vs -64.0%).
Civista Bancshares, Inc. is a US-based bank holding company operating primarily across the Midwest region. It provides a full suite of personal and commercial banking services including deposit accounts, mortgage, consumer and commercial lending products, as well as wealth management solutions, serving retail consumers, small and medium-sized local businesses and community client segments.
Telesat, formerly Telesat Canada, is a Canadian satellite communications company founded on May 2, 1969. The company is headquartered in Ottawa.
CIVB vs TSAT — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | ||
|---|---|---|
| Revenue | $47.3M | $73.8M |
| Net Profit | $15.0M | $-88.4M |
| Gross Margin | — | 95.3% |
| Operating Margin | — | 5.9% |
| Net Margin | 31.7% | -119.8% |
| Revenue YoY | — | — |
| Net Profit YoY | 47.4% | — |
| EPS (diluted) | $0.72 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $47.3M | — | ||
| Q4 25 | $46.3M | — | ||
| Q3 25 | $44.2M | $73.8M | ||
| Q2 25 | $41.4M | $77.5M | ||
| Q1 25 | $40.6M | $152.2M | ||
| Q4 24 | $40.4M | — | ||
| Q3 24 | $39.3M | — | ||
| Q2 24 | $38.1M | $363.2M |
| Q1 26 | $15.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $12.8M | $-88.4M | ||
| Q2 25 | $11.0M | $55.1M | ||
| Q1 25 | $10.2M | $-52.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | $8.4M | — | ||
| Q2 24 | $7.1M | $547.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 95.3% | ||
| Q2 25 | — | 95.9% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 31.8% | — | ||
| Q3 25 | 35.4% | 5.9% | ||
| Q2 25 | 31.1% | 16.8% | ||
| Q1 25 | 29.4% | — | ||
| Q4 24 | 28.2% | — | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | 21.2% | — |
| Q1 26 | 31.7% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 28.9% | -119.8% | ||
| Q2 25 | 26.6% | 71.2% | ||
| Q1 25 | 25.0% | -34.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | 21.3% | — | ||
| Q2 24 | 18.5% | 150.7% |
| Q1 26 | $0.72 | — | ||
| Q4 25 | $0.59 | — | ||
| Q3 25 | $0.68 | — | ||
| Q2 25 | $0.71 | — | ||
| Q1 25 | $0.66 | — | ||
| Q4 24 | $0.62 | — | ||
| Q3 24 | $0.53 | — | ||
| Q2 24 | $0.45 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | ||
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $352.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $553.9M | $1.6B |
| Total Assets | $4.3B | $5.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $352.3M | ||
| Q2 25 | — | $399.6M | ||
| Q1 25 | — | $552.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $1.7B |
| Q1 26 | $553.9M | — | ||
| Q4 25 | $543.5M | — | ||
| Q3 25 | $499.0M | $1.6B | ||
| Q2 25 | $404.1M | $1.7B | ||
| Q1 25 | $397.4M | $2.5B | ||
| Q4 24 | $388.5M | — | ||
| Q3 24 | $394.4M | — | ||
| Q2 24 | $373.8M | $2.4B |
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.3B | — | ||
| Q3 25 | $4.1B | $5.1B | ||
| Q2 25 | $4.2B | $4.9B | ||
| Q1 25 | $4.1B | $6.9B | ||
| Q4 24 | $4.1B | — | ||
| Q3 24 | $4.1B | — | ||
| Q2 24 | $4.0B | $6.3B |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CIVB
| Net Interest Income | $37.8M | 80% |
| Noninterest Income | $9.4M | 20% |
TSAT
Segment breakdown not available.